Sei Investments Co. Has $89.16 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sei Investments Co. grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 7.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 271,387 shares of the medical research company's stock after buying an additional 18,873 shares during the quarter. Sei Investments Co. owned about 0.97% of Bio-Rad Laboratories worth $89,156,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BIO. Wealthfront Advisers LLC acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at $342,686,000. Point72 Asset Management L.P. purchased a new stake in Bio-Rad Laboratories during the third quarter valued at about $83,681,000. Wedge Capital Management L L P NC purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter worth approximately $28,740,000. Proficio Capital Partners LLC purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at approximately $9,820,000. Finally, DAVENPORT & Co LLC boosted its stake in Bio-Rad Laboratories by 48.8% in the 4th quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company's stock worth $27,817,000 after purchasing an additional 27,780 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BIO shares. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Royal Bank of Canada restated an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $395.20.

Remove Ads

Bio-Rad Laboratories Price Performance

Shares of BIO stock traded up $2.33 during mid-day trading on Thursday, reaching $247.65. The company's stock had a trading volume of 186,595 shares, compared to its average volume of 289,633. The firm's 50-day moving average is $297.47 and its two-hundred day moving average is $323.57. The company has a market cap of $6.94 billion, a P/E ratio of -3.81 and a beta of 0.98. Bio-Rad Laboratories, Inc. has a 1-year low of $243.76 and a 1-year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.